CA2441492A1 - Rho-kinase inhibitors - Google Patents
Rho-kinase inhibitors Download PDFInfo
- Publication number
- CA2441492A1 CA2441492A1 CA002441492A CA2441492A CA2441492A1 CA 2441492 A1 CA2441492 A1 CA 2441492A1 CA 002441492 A CA002441492 A CA 002441492A CA 2441492 A CA2441492 A CA 2441492A CA 2441492 A1 CA2441492 A1 CA 2441492A1
- Authority
- CA
- Canada
- Prior art keywords
- indazol
- quinazolinamine
- quinazolinyl
- amine
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
The present invention relates to compounds (see formula I) wherein A, B, X, Y, R1, R2, R3, R4, R5, a, b, c and p are as defined herein, and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors.
The compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction and treating other indications mediated by Rho-kinase, e.g.
coronary heart disease.
The compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction and treating other indications mediated by Rho-kinase, e.g.
coronary heart disease.
Claims (28)
1. A compound of Formula I
wherein Y is =N- or =CR17, X is -(CH2) x-, -O-(CH2)n-, -S-(CH2)n-, -NR7-CO-(CH2)n-, -NR7-SO2-(CH2)n-, -NR7-(CH2)n-, or -(O)C-NR7-, each n is an integer which is independently 0, 1, 2 or 3, x is 0-3 p is 0-3 a and c are each independently -CR5=, -N=, or -NR6-, wherein one of a or c is -NR6-, and b is -CR5= or -N=;
A is H, halogen, -CO-OR8, -CO-R8, cyano, -OR8, -NR8R9, -CO-NR8R9, -NR8-CO-R9, -CO-OR9, -NR8-SO2-R9, -SR8, -SO2-R8, -SO2-NR8R9, NR8-CO-NHR9, or A is a 3-20 atom, cyclic or polycyclic moiety, containing 1-4 rings, which optionally contain 1-3 N, O or S atoms per ring, and may optionally be aryl or heteroaryl, which cyclic or polycyclic moiety may optionally be substituted up to 3 times by (i) C1-C10 alkyl or C2-C10-alkenyl, each optionally substituted with halogen up to perhalo; (ii) C3-C10 cycloalkyl; (iii) aryl; (iv) heteroaryl; (v) halogen; (vi) -CO-OR8; (vii) -CO-R8; (viii) cyano;
(ix) -OR8, (x) (x) -NR8R13; (xi) nitro; (xii) -CO-NR8R9; (xiii) -C1-10-alkyl-NR8R9;(xiv) -NR8-CO-R12; (xv) -NR8-CO-OR9; (xvi) -NR8-SO2-R9; (xvii) -SR8; (xviii) -SO2-R8; (xix) -SO2-NR8R9;
or (xx) NR8-CO-NHR9;
Ring B is optionally independently substituted up to 3 times in any position by R5, R1, and R6-R11 are each independently hydrogen or C1-6 alkyl, R2-R5 are each independently (i) hydrogen, (ii) C1-10 alkyl or C2-10-alkenyl each optionally substituted by amino, N-lower alkylamino, N,N-dilower alkylamino, N-lower alkanoylamino, hydroxy, cyano, -COOR10, -COR14, -OCOR14, -OR10, C5-10-heteroaryl, C5-10-heteroaryloxy, or C5-10-heteroaryl-C1-10-alkoxy, halogen up to perhalo; (iii) C3-C10 cycloalkyl, in which 1-3 carbon atoms are optionally independently replaced by O, N or S; (iv) C3-10-cycloalkenyl; (v) partially unsaturated C5-10-heterocyclyl; (vi) aryl; (vii) heteroaryl; (viii) halogen; (ix) -CO-OR10; (x) -OCOR10; (xi) -OCO2R10; (xii) -CHO; (xiii) cyano; (xiv) -OR16; (xv) -NR10R15;
(xvi) nitro; (xvii) -CO-NR10R11; (xviii) -NR10-CO-R12; (xix) -NR10-CO-OR11;
(xx) -NR10-SO2-R12; (xxi) -SR16; (xxii) -SOR16; (xxiii) -SO2-R16; (xxiv) -SO2-NR10R11;
(xxv) NR10-CO-NHR11; (xxvi) amidino; (xxvii) guanidino; (xxviii) sulfo; (xxix) -B(OH)2;
(xxx) -OCON(R10)2; or (xxxi) NR10CON(R10)2;
R12 is H, C1-6-alkyl or C5-10-aryl, R13 is H, C1-6-alkyl or C1-6-alkoxy, R14 is C1-6 alkyl or phenyl;
R15 is C1-6 alkyl, halogen, amino, N-lower alkyl amino, N,N-dilower alkylamino, N-lower alkanoylamino, OH, CN, COOR10, -COR14 or -OCOR14;
R16 is hydrogen, C1-6-alkyl optionally substituted by halogen, up to perhalo, or C5-10-heteroaryl; and R17 is H, C1-6 alkyl or CN, or a pharmaceutically acceptable salt thereof, with the provisos that A is not hydrogen when x is 0, and that Formula I is not
wherein Y is =N- or =CR17, X is -(CH2) x-, -O-(CH2)n-, -S-(CH2)n-, -NR7-CO-(CH2)n-, -NR7-SO2-(CH2)n-, -NR7-(CH2)n-, or -(O)C-NR7-, each n is an integer which is independently 0, 1, 2 or 3, x is 0-3 p is 0-3 a and c are each independently -CR5=, -N=, or -NR6-, wherein one of a or c is -NR6-, and b is -CR5= or -N=;
A is H, halogen, -CO-OR8, -CO-R8, cyano, -OR8, -NR8R9, -CO-NR8R9, -NR8-CO-R9, -CO-OR9, -NR8-SO2-R9, -SR8, -SO2-R8, -SO2-NR8R9, NR8-CO-NHR9, or A is a 3-20 atom, cyclic or polycyclic moiety, containing 1-4 rings, which optionally contain 1-3 N, O or S atoms per ring, and may optionally be aryl or heteroaryl, which cyclic or polycyclic moiety may optionally be substituted up to 3 times by (i) C1-C10 alkyl or C2-C10-alkenyl, each optionally substituted with halogen up to perhalo; (ii) C3-C10 cycloalkyl; (iii) aryl; (iv) heteroaryl; (v) halogen; (vi) -CO-OR8; (vii) -CO-R8; (viii) cyano;
(ix) -OR8, (x) (x) -NR8R13; (xi) nitro; (xii) -CO-NR8R9; (xiii) -C1-10-alkyl-NR8R9;(xiv) -NR8-CO-R12; (xv) -NR8-CO-OR9; (xvi) -NR8-SO2-R9; (xvii) -SR8; (xviii) -SO2-R8; (xix) -SO2-NR8R9;
or (xx) NR8-CO-NHR9;
Ring B is optionally independently substituted up to 3 times in any position by R5, R1, and R6-R11 are each independently hydrogen or C1-6 alkyl, R2-R5 are each independently (i) hydrogen, (ii) C1-10 alkyl or C2-10-alkenyl each optionally substituted by amino, N-lower alkylamino, N,N-dilower alkylamino, N-lower alkanoylamino, hydroxy, cyano, -COOR10, -COR14, -OCOR14, -OR10, C5-10-heteroaryl, C5-10-heteroaryloxy, or C5-10-heteroaryl-C1-10-alkoxy, halogen up to perhalo; (iii) C3-C10 cycloalkyl, in which 1-3 carbon atoms are optionally independently replaced by O, N or S; (iv) C3-10-cycloalkenyl; (v) partially unsaturated C5-10-heterocyclyl; (vi) aryl; (vii) heteroaryl; (viii) halogen; (ix) -CO-OR10; (x) -OCOR10; (xi) -OCO2R10; (xii) -CHO; (xiii) cyano; (xiv) -OR16; (xv) -NR10R15;
(xvi) nitro; (xvii) -CO-NR10R11; (xviii) -NR10-CO-R12; (xix) -NR10-CO-OR11;
(xx) -NR10-SO2-R12; (xxi) -SR16; (xxii) -SOR16; (xxiii) -SO2-R16; (xxiv) -SO2-NR10R11;
(xxv) NR10-CO-NHR11; (xxvi) amidino; (xxvii) guanidino; (xxviii) sulfo; (xxix) -B(OH)2;
(xxx) -OCON(R10)2; or (xxxi) NR10CON(R10)2;
R12 is H, C1-6-alkyl or C5-10-aryl, R13 is H, C1-6-alkyl or C1-6-alkoxy, R14 is C1-6 alkyl or phenyl;
R15 is C1-6 alkyl, halogen, amino, N-lower alkyl amino, N,N-dilower alkylamino, N-lower alkanoylamino, OH, CN, COOR10, -COR14 or -OCOR14;
R16 is hydrogen, C1-6-alkyl optionally substituted by halogen, up to perhalo, or C5-10-heteroaryl; and R17 is H, C1-6 alkyl or CN, or a pharmaceutically acceptable salt thereof, with the provisos that A is not hydrogen when x is 0, and that Formula I is not
2. A compound according to claim 1, wherein A is a 5-12 carbon-atom aromatic ring or ring system containing 1-3 rings, at least one of which is aromatic, in which 1-4 carbon atoms in one or more of the rings is optionally replaced by oxygen, nitrogen or sulfur atoms.
3. A compound according to claim 2, wherein each ring in A has 3-7 atoms.
4. A compound according to claim 1, wherein A is 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or 5-yl, 1,2,4-triazol-1-, -3- or 5-yl, f-or 5-tetrazolyl, 1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or 5-yl, 1,3,4-thiadiazol-3- or 5-yl, 1,2,3-thiadiazol-4- or 5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6-or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5- 6- or 7-benzisoxazolyl, 1-, 3-, 4-, 5-,6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 4-, 5-, 6-or 7-benz-1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl, or 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 2- or 3-thienyl, 1,3,4-thiadiazolyl, 3-pyrryl, 3-pyrazolyl, 2-thiazolyl or 5-thiazolyl.
5. A compound according to claim 1, wherein A is cyclohexyl; or C5-12-aryl or heteroaryl each independently optionally substituted up to three times by (i) C1-C10-alkyl or C2-10-alkenyl each optionally substituted with halogen up to perhalo; (ii) C3-C10 cycloalkyl;
(iii) C5-12-aryl optionally substituted by 1-3 halogen atoms; (iv) C5-12-heteroaryl; (v) halogen;
(vi) -CO-OR8; (vii) -CO-R8; (viii) cyano; (ix) -OR8; (x) -NR8R13; (xi) nitro;
(xii) -CO-NR8R9;
(xiii) -C1-10-alkyl-NR8R9; (xiv) -NR8-CO-R12; (xv) -NR8-CO-OR9; (xvi) -NR8-SO2-R9; (xvii) -SR8; (xviii) -SO2-R8; (xix) -SO2-NR8R9, or (xx) NR8-CO-NHR9.
(iii) C5-12-aryl optionally substituted by 1-3 halogen atoms; (iv) C5-12-heteroaryl; (v) halogen;
(vi) -CO-OR8; (vii) -CO-R8; (viii) cyano; (ix) -OR8; (x) -NR8R13; (xi) nitro;
(xii) -CO-NR8R9;
(xiii) -C1-10-alkyl-NR8R9; (xiv) -NR8-CO-R12; (xv) -NR8-CO-OR9; (xvi) -NR8-SO2-R9; (xvii) -SR8; (xviii) -SO2-R8; (xix) -SO2-NR8R9, or (xx) NR8-CO-NHR9.
6. A compound according to claim 1, wherein A is phenyl, pyridyl, pyrimidinyl, oxazolyl, furyl, thienyl, pyrrolyl, imidazolyl, isoxazolyl and pyrazinyl, each independently substituted up to three times by halogen, C1-10-alkyl, C1-10-alkoxyphenyl, naphthyl, -OR10, -C1-10-alkyl-NR8R9, -NR10-SO2-R11, wherein each Z independently is halogen, hydroxy, hydroxy-C1-10-alkyl, -CN, -NO2, C1-10-alkoxycarboxyl, -NR10-CO-R11, or -NR10-CO-OR11, and y is 1-3
7. A compound according to claim 1, wherein A is wherein R15 is H; phenyl optionally substituted by C1-10-alkyl, C1-10-alkoxy, alkylcarboxyl, or halogen; benzyl; pyrimidyl or pyridyl; and R16 is H, phenyl, -COOR10,
8. A compound according to claim 1, wherein R5 in a, b or c is hydrogen or C1-10-alkyl or C2-10-alkyl optionally substituted by amino, N-lower alkylamino, N,N-dilower alkylamino, N-lower alkanoylamino, hydroxy, cyano, -COOR10, -COR14, -OCOR14, -OR10, C5-10-heteroaryl, C5-10-heteroaryloxy, or C5-10-heteroaryl-C1-10-alkoxy, halogen up to perhalo; (iii) C3-C10 cycloalkyl, in which 1-3 carbon atoms are optionally independently replaced by O, N
or S; (iv) C3-10-cycloalkenyl; (v) partially unsaturated C5-10-heterocyclyl;
(vi) aryl; (vii) heteroaryl; (viii) halogen; (ix) -CO-OR10; (x) -OCOR10; (xi) -OCO2R10; (xii) -CHO; (xiii) cyano; (xiv) -OR16; (xv) -NR10R15; (xvi) nitro; (xvii) -CO-NR10R11; (xviii) -NR10-CO-R12;
(xix) -NR10-CO-OR16; (xx) -NR10-SO2-R12; (xxi) -SR16; (xxii) -SOR16; (xxiii) -SO2-R16;
(xxiv) -SO2-NR10R11; (xxv) NR10-CO-NHR11; (xxvi) amidino; (xxvii) guanidino;
(xxviii) sulfo; (xxix) -B(OH)2; (xxx) -OCON(R10)2; or (xxxi) -NR10CON(R10)2.
or S; (iv) C3-10-cycloalkenyl; (v) partially unsaturated C5-10-heterocyclyl;
(vi) aryl; (vii) heteroaryl; (viii) halogen; (ix) -CO-OR10; (x) -OCOR10; (xi) -OCO2R10; (xii) -CHO; (xiii) cyano; (xiv) -OR16; (xv) -NR10R15; (xvi) nitro; (xvii) -CO-NR10R11; (xviii) -NR10-CO-R12;
(xix) -NR10-CO-OR16; (xx) -NR10-SO2-R12; (xxi) -SR16; (xxii) -SOR16; (xxiii) -SO2-R16;
(xxiv) -SO2-NR10R11; (xxv) NR10-CO-NHR11; (xxvi) amidino; (xxvii) guanidino;
(xxviii) sulfo; (xxix) -B(OH)2; (xxx) -OCON(R10)2; or (xxxi) -NR10CON(R10)2.
9. A compound according to claim 1, wherein Y is N and R1 is H.
10. A compound according to claim 9, wherein a is -NR6-, R6 is H, and c is -N=.
11. A compound according to claim 10, wherein p is 0 and R1-4 are H.
12. A compound according to claim 11, wherein X is -(CH2)x- and x is 0.
13. A compound according to claim 12, wherein A is biphenyl optionally substituted by halogen.
14. A compound according to claim 1, of the formula:
2-(2,4-dichlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(4-chlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 1-{4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl}ethanone, N-(1H-indazol-5-yl)-2-[4-(trifluoromethyl)phenyl]-4-quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine, 2-(3,4-dichlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(1-naphthyl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(3,4,5-trimethoxyphenyl)-4-quinazolinamine, 2-(1-benzofuran-2-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H indazol-5-yl)-2-(2-thienyl)-4-quinazolinamine N-(1H indazol-5-yl)-2-(3-thienyl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(2-methoxyphenyl)-4-quinazolinamine, 2-(4-ethoxyphenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(3,5-dimethyl-4-isoxazolyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(1-benzothieN-2-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-quinazolinamine, 4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenol, 2-dibenzo[b,d]furan-1-yl-N (1H-indazol-5-yl)-4-quinazolinamine, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 7-chloro-N-(1H-indazol-5-yl)-2-phenyl-4-quinazolinamine, N-(1H-indazol-5-yl)-6-nitro-2-phenyl-4-quinazolinamine, 2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-nitro-4-quinazolinamine, 6-chloro-N-(1H-indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine, 6-chloro-N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-quinazolinamine, 6-chloro-2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 6-chloro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(2-quinoxalinyl)-4-quinazolinamine, 5-fluoro-N-(1H-indazol-5-yl)-2-(2-methylphenyl)-4-quinazolinamine, 5-fluoro-2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(3-chlorophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(4-bromophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine, 5-fluoro-N-(1H-indazol-5-yl)-2-(3-methylphenyl)-4-quinazolinamine hydrochloride, 2-(3-bromophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine hydrochloride, 2-(2-chlorophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine, 5-fluoro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine bis(trifluoroacetate), 5-fluoro-N-(1H-indazol-5-yl)-2-(2-quinoxalinyl)-4-quinazolinamine tris(trifluoroacetate), 5-fluoro-N-(1H-indazol-5-yl)-2-(1-naphthyl)-4-quinazolinamine bis(trifluoroacetate), 5-fluoro-N-(1H-indazol-5-yl)-2-(2-naphthyl)-4-quinazolinamine bis(trifluoroacetate), 5-fluoro-N-(1H-indazol-5-yl)-2-(4-pyridinyl)-4-quinazolinamine tris(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(2-quinoxalinyl)-4-quinazolinamine, 2-(3-chlorophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine, 2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine, N-(1H-indazol-5-yl)-7-methyl-2-(4-methylphenyl)-4-quinazolinamine", 2-(4-bromophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-7-methyl-4-quinazolinamine, N-(1H-indazol-5-yl)-7-methyl-2-(2-methylphenyl)-4-quinazolinamine bis(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(3-methylphenyl)-4-quinazolinamine bis(trifluoroacetate), N-[2-(3-fluorophenyl)-7-methyl-4-quinazolinyl]-N-(1H-indazol-5-yl)amine bis(trifluoroacetate), 2-(3-bromophenyl)-N-(1H-indazol-5-yl)-7-methyl-quinazolinamine bis(trifluoroacetate), N-[2-(2-chlorophenyl)-7-methyl-4-quinazolinyl]-N-(1H-indazol-5-yl)amine bis(trifluoroacetate), N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-7-methyl-4-quinazolinamine bis(trifluoroacetate), 2-(3-furyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine bis(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(1-naphthyl)-4-quinazolinamine bis(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(2-naphthyl)-4-quinazolinamine bis(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(3-pyridinyl)-4-quinazolinamine tris(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(4-pyridinyl)-4-quinazolinamine tris(trifluoroacetate), 7-chloro-2-(3-chlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 7-chloro-N-(1H-indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine ,2-(4-bromophenyl)-7-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine, 7-chloro-N-(1H-indazol-5-yl)-2-(3-methylphenyl)-4-quinazolinamine hydrochloride, 7-chloro-2-(3-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine bis(trifluoroacetate), 2-(3-bromophenyl)-7-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine bis(trifluoroacetate), 7-chloro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine bis(trifluoroacetate), N-[7-chloro-2-(2-furyl)-4-quinazolinyl]-N-(1H-indazol-5-yl)amine bis(trifluoroacetate), 7-chloro-N-(1H-indazol-5-yl)-2-(2-quinoxalinyl)-4-quinazolinamine tris(trifluoroacetate), 7-chloro-N-(1H-indazol-5-yl)-2-(1-naphthyl)-4-quinazolinamine bis(trifluoroacetate), 7-chloro-N-(1H-indazol-5-yl)-2-(2-naphthyl)-4-quinazolinamine bis(trifluoroacetate), 7-chloro-N-(1H
indazol-5-yl)-2-(3-pyridinyl)-4-quinazolinamine tris(trifluoroacetate), 2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6,7-dimethoxy-4-quinazolinamine, 2-(1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-6,7-dimethoxy-4-quinazolinamine, N-(1H-indazol-5-yl)-6,7-dimethoxy-2-(3-methoxyphenyl)-4-quinazolinamine, N-(1H-indazol-5-yl)-6,7-dimethoxy-2-(4-vinylphenyl)-4-quinazolinamine, 2-(4-ethoxyphenyl)-N-(1H-indazol-5-yl)-6,7-dimethoxy-4-quinazolinamine, N-cyclopentyl-4-(1H-indazol-5-ylamino)-2-quinazolinecarboxamide, N-(3-fluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,4-difluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2-fluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(4-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(6,7-dimethoxy-2-{[4-(trifluoromethyl)phenyl]amino}-4-quinazolinyl)-N-(1H-indazol-5-yl)amine, N-(6,7-dimethoxy-2-{[4-(trifluoromethyl)benzyl]amino}-4-quinazolinyl)-N-(1H-indazol-5-yl)amine, N-[3-fluoro-5-(trifluoromethyl)benzyl]-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3-fluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,4-difluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(4-fluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,6-difluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3,5-difluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,6-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,5-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,4-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,3-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3,4-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3,5-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-{6,7-dimethoxy-2-[(2,3,4-trifluorophenyl)amino]-4-quinazolinyl}-N-(1H-indazol-5-yl)amine, N-{6,7-dimethoxy-2-[(2,4,5-trifluorophenyl)amino]-4-quinazolinyl}-N-(1H-indazol-5-yl)amine, N-{6,7-dimethoxy-2-[(2,4,6-trifluorophenyl)amino]-4-quinazolinyl}-N-(1H-indazol-5-yl)amine, N-{6,7-dimethoxy-2-[(2,3,6-trifluorophenyl)amino]-4-quinazolinyl}-N-(1H-indazol-5-yl)amine, N-(4-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, 2-(3-aminophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl}isonicotinamide, N-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl}acetamide, N-(4-chlorophenyl)-N-[4-(1H-indazol-5-ylamino)-quinazolinyl]amine, N-(3-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(2-chlorophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(3-fluorophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(2-fluorophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(1H-indazol-5-yl)-N-{2-[(2-methoxyphenyl)amino]-4-quinazolinyl}amine, N-(1H-indazol-5-yl)-N-{2-[(3-methoxyphenyl)amino]-4-quinazolinyl}amine, N-(3-chlorophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(4-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(1H-indazol-5-yl)-N-(2-{[3-(trifluoromethyl)phenyl]amino}-4-quinazolinyl)amine, N-(1H-indazol-5-yl)-N-{2-[(4-phenoxyphenyl)amino]-4-quinazolinyl}amine, N-(1H-indazol-5-yl)-N-(2-{[4-(trifluoromethoxy)phenyl]amino}-4-quinazolinyl)amine, N-(1H-indazol-5-yl)-N-(2-{[3-(trifluoromethoxy)phenyl]amino}-4-quinazolinyl)amine, N-(4-fluorophenyl)-N-[4-(1H
indazol-5-ylamino)-2-quinazolinyl]amine, N-(2-anilino-4-quinazolinyl)-N-(1H-indazol-5-yl)amine, 2-[4-(2-chlorophenyl)-1-piperazinyl]-N-(1H-indazol-5-yl)-4-quinazolinamine, N
(1H-indazol-5-yl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]-4-quinazolinamine, N-(1H-indazol-5-yl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-4-quinazolinamine, 1-(4-{4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]-1-piperazinyl}phenyl)ethanone, 4-(1H-indazol-5-ylamino)-2-quinazolinecarboxamide", 4-(1H-indazol-5-ylamino)-N-(4-pyridinyl)-2-quinazolinecarboxamide, 4-(1H-indazol-5-ylamino)-N-(4-methoxyphenyl)-2-quinazolinecarboxamide, N-cyclohexyl-4-(1H-indazol-5-ylamino)-2-quinazolinecarboxamide, N-cyclopentyl-4-(1H-indazol-5-ylamino)-2-quinazolinecarboxamide, 4-(1H-indazol-5-ylamino)-N-(2-pyridinyl)-2-quinazolinecarboxamide, 4-(1H-indazol-5-ylamino)-N-(3-quinolinyl)-2-quinazolinecarboxamide, 4-(1H-indazol-5-ylamino)-N-methyl-2-quinazolinecarboxamide, N
(1H-indazol-5-yl)-2-(4-morpholinylcarbonyl)-4-quinazolinamine, 2-(2,3-dihydro-benzofuran-5-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-cyclopropyl-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(trifluoromethyl)-4-quinazolinamine, N-(3-ethyl-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-quinazolinamine, 2-chloro-N-(3-ethyl-1H
indazol-5-yl)-4-quinazolinamine, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine dihydrochloride, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine dimethanesulfonate, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine benzenesulfonate, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine 4-methylbenzenesulfonate, or 2-dibenzo[b,d]furan-1-yl-N-(1H-indazol-5-yl)-4-quinazolinamine trifluoroacetate, 2-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine.
2-(2,4-dichlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(4-chlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 1-{4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl}ethanone, N-(1H-indazol-5-yl)-2-[4-(trifluoromethyl)phenyl]-4-quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine, 2-(3,4-dichlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(1-naphthyl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(3,4,5-trimethoxyphenyl)-4-quinazolinamine, 2-(1-benzofuran-2-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H indazol-5-yl)-2-(2-thienyl)-4-quinazolinamine N-(1H indazol-5-yl)-2-(3-thienyl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(2-methoxyphenyl)-4-quinazolinamine, 2-(4-ethoxyphenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(3,5-dimethyl-4-isoxazolyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(1-benzothieN-2-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-quinazolinamine, 4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenol, 2-dibenzo[b,d]furan-1-yl-N (1H-indazol-5-yl)-4-quinazolinamine, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 7-chloro-N-(1H-indazol-5-yl)-2-phenyl-4-quinazolinamine, N-(1H-indazol-5-yl)-6-nitro-2-phenyl-4-quinazolinamine, 2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-nitro-4-quinazolinamine, 6-chloro-N-(1H-indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine, 6-chloro-N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-quinazolinamine, 6-chloro-2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 6-chloro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine, 2-(4-bromophenyl)-6-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(2-quinoxalinyl)-4-quinazolinamine, 5-fluoro-N-(1H-indazol-5-yl)-2-(2-methylphenyl)-4-quinazolinamine, 5-fluoro-2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(3-chlorophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-(4-bromophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine, 5-fluoro-N-(1H-indazol-5-yl)-2-(3-methylphenyl)-4-quinazolinamine hydrochloride, 2-(3-bromophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine hydrochloride, 2-(2-chlorophenyl)-5-fluoro-N-(1H-indazol-5-yl)-4-quinazolinamine, 5-fluoro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine bis(trifluoroacetate), 5-fluoro-N-(1H-indazol-5-yl)-2-(2-quinoxalinyl)-4-quinazolinamine tris(trifluoroacetate), 5-fluoro-N-(1H-indazol-5-yl)-2-(1-naphthyl)-4-quinazolinamine bis(trifluoroacetate), 5-fluoro-N-(1H-indazol-5-yl)-2-(2-naphthyl)-4-quinazolinamine bis(trifluoroacetate), 5-fluoro-N-(1H-indazol-5-yl)-2-(4-pyridinyl)-4-quinazolinamine tris(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(2-quinoxalinyl)-4-quinazolinamine, 2-(3-chlorophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine, 2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine, N-(1H-indazol-5-yl)-7-methyl-2-(4-methylphenyl)-4-quinazolinamine", 2-(4-bromophenyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-7-methyl-4-quinazolinamine, N-(1H-indazol-5-yl)-7-methyl-2-(2-methylphenyl)-4-quinazolinamine bis(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(3-methylphenyl)-4-quinazolinamine bis(trifluoroacetate), N-[2-(3-fluorophenyl)-7-methyl-4-quinazolinyl]-N-(1H-indazol-5-yl)amine bis(trifluoroacetate), 2-(3-bromophenyl)-N-(1H-indazol-5-yl)-7-methyl-quinazolinamine bis(trifluoroacetate), N-[2-(2-chlorophenyl)-7-methyl-4-quinazolinyl]-N-(1H-indazol-5-yl)amine bis(trifluoroacetate), N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-7-methyl-4-quinazolinamine bis(trifluoroacetate), 2-(3-furyl)-N-(1H-indazol-5-yl)-7-methyl-4-quinazolinamine bis(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(1-naphthyl)-4-quinazolinamine bis(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(2-naphthyl)-4-quinazolinamine bis(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(3-pyridinyl)-4-quinazolinamine tris(trifluoroacetate), N-(1H-indazol-5-yl)-7-methyl-2-(4-pyridinyl)-4-quinazolinamine tris(trifluoroacetate), 7-chloro-2-(3-chlorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 7-chloro-N-(1H-indazol-5-yl)-2-(4-methylphenyl)-4-quinazolinamine ,2-(4-bromophenyl)-7-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine, 7-chloro-N-(1H-indazol-5-yl)-2-(3-methylphenyl)-4-quinazolinamine hydrochloride, 7-chloro-2-(3-fluorophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine bis(trifluoroacetate), 2-(3-bromophenyl)-7-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine bis(trifluoroacetate), 7-chloro-N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-4-quinazolinamine bis(trifluoroacetate), N-[7-chloro-2-(2-furyl)-4-quinazolinyl]-N-(1H-indazol-5-yl)amine bis(trifluoroacetate), 7-chloro-N-(1H-indazol-5-yl)-2-(2-quinoxalinyl)-4-quinazolinamine tris(trifluoroacetate), 7-chloro-N-(1H-indazol-5-yl)-2-(1-naphthyl)-4-quinazolinamine bis(trifluoroacetate), 7-chloro-N-(1H-indazol-5-yl)-2-(2-naphthyl)-4-quinazolinamine bis(trifluoroacetate), 7-chloro-N-(1H
indazol-5-yl)-2-(3-pyridinyl)-4-quinazolinamine tris(trifluoroacetate), 2-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6,7-dimethoxy-4-quinazolinamine, 2-(1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-6,7-dimethoxy-4-quinazolinamine, N-(1H-indazol-5-yl)-6,7-dimethoxy-2-(3-methoxyphenyl)-4-quinazolinamine, N-(1H-indazol-5-yl)-6,7-dimethoxy-2-(4-vinylphenyl)-4-quinazolinamine, 2-(4-ethoxyphenyl)-N-(1H-indazol-5-yl)-6,7-dimethoxy-4-quinazolinamine, N-cyclopentyl-4-(1H-indazol-5-ylamino)-2-quinazolinecarboxamide, N-(3-fluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,4-difluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2-fluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(4-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(6,7-dimethoxy-2-{[4-(trifluoromethyl)phenyl]amino}-4-quinazolinyl)-N-(1H-indazol-5-yl)amine, N-(6,7-dimethoxy-2-{[4-(trifluoromethyl)benzyl]amino}-4-quinazolinyl)-N-(1H-indazol-5-yl)amine, N-[3-fluoro-5-(trifluoromethyl)benzyl]-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3-fluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,4-difluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(4-fluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,6-difluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3,5-difluorobenzyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,6-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,5-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,4-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(2,3-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3,4-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-(3,5-difluorophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, N-{6,7-dimethoxy-2-[(2,3,4-trifluorophenyl)amino]-4-quinazolinyl}-N-(1H-indazol-5-yl)amine, N-{6,7-dimethoxy-2-[(2,4,5-trifluorophenyl)amino]-4-quinazolinyl}-N-(1H-indazol-5-yl)amine, N-{6,7-dimethoxy-2-[(2,4,6-trifluorophenyl)amino]-4-quinazolinyl}-N-(1H-indazol-5-yl)amine, N-{6,7-dimethoxy-2-[(2,3,6-trifluorophenyl)amino]-4-quinazolinyl}-N-(1H-indazol-5-yl)amine, N-(4-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-6,7-dimethoxy-2-quinazolinyl]amine, 2-(3-aminophenyl)-N-(1H-indazol-5-yl)-4-quinazolinamine, N-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl}isonicotinamide, N-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenyl}acetamide, N-(4-chlorophenyl)-N-[4-(1H-indazol-5-ylamino)-quinazolinyl]amine, N-(3-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(2-chlorophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(3-fluorophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(2-fluorophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(1H-indazol-5-yl)-N-{2-[(2-methoxyphenyl)amino]-4-quinazolinyl}amine, N-(1H-indazol-5-yl)-N-{2-[(3-methoxyphenyl)amino]-4-quinazolinyl}amine, N-(3-chlorophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(4-bromophenyl)-N-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]amine, N-(1H-indazol-5-yl)-N-(2-{[3-(trifluoromethyl)phenyl]amino}-4-quinazolinyl)amine, N-(1H-indazol-5-yl)-N-{2-[(4-phenoxyphenyl)amino]-4-quinazolinyl}amine, N-(1H-indazol-5-yl)-N-(2-{[4-(trifluoromethoxy)phenyl]amino}-4-quinazolinyl)amine, N-(1H-indazol-5-yl)-N-(2-{[3-(trifluoromethoxy)phenyl]amino}-4-quinazolinyl)amine, N-(4-fluorophenyl)-N-[4-(1H
indazol-5-ylamino)-2-quinazolinyl]amine, N-(2-anilino-4-quinazolinyl)-N-(1H-indazol-5-yl)amine, 2-[4-(2-chlorophenyl)-1-piperazinyl]-N-(1H-indazol-5-yl)-4-quinazolinamine, N
(1H-indazol-5-yl)-2-[4-(2-pyrimidinyl)-1-piperazinyl]-4-quinazolinamine, N-(1H-indazol-5-yl)-2-[4-(2-methoxyphenyl)-1-piperazinyl]-4-quinazolinamine, 1-(4-{4-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]-1-piperazinyl}phenyl)ethanone, 4-(1H-indazol-5-ylamino)-2-quinazolinecarboxamide", 4-(1H-indazol-5-ylamino)-N-(4-pyridinyl)-2-quinazolinecarboxamide, 4-(1H-indazol-5-ylamino)-N-(4-methoxyphenyl)-2-quinazolinecarboxamide, N-cyclohexyl-4-(1H-indazol-5-ylamino)-2-quinazolinecarboxamide, N-cyclopentyl-4-(1H-indazol-5-ylamino)-2-quinazolinecarboxamide, 4-(1H-indazol-5-ylamino)-N-(2-pyridinyl)-2-quinazolinecarboxamide, 4-(1H-indazol-5-ylamino)-N-(3-quinolinyl)-2-quinazolinecarboxamide, 4-(1H-indazol-5-ylamino)-N-methyl-2-quinazolinecarboxamide, N
(1H-indazol-5-yl)-2-(4-morpholinylcarbonyl)-4-quinazolinamine, 2-(2,3-dihydro-benzofuran-5-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine, 2-cyclopropyl-N-(1H-indazol-5-yl)-4-quinazolinamine, N-(1H-indazol-5-yl)-2-(trifluoromethyl)-4-quinazolinamine, N-(3-ethyl-1H-indazol-5-yl)-2-(4-methoxyphenyl)-4-quinazolinamine, 2-chloro-N-(3-ethyl-1H
indazol-5-yl)-4-quinazolinamine, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine dihydrochloride, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine dimethanesulfonate, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine benzenesulfonate, 2-(2-fluoro-1,1'-biphenyl-4-yl)-N-(1H-indazol-5-yl)-4-quinazolinamine 4-methylbenzenesulfonate, or 2-dibenzo[b,d]furan-1-yl-N-(1H-indazol-5-yl)-4-quinazolinamine trifluoroacetate, 2-chloro-N-(1H-indazol-5-yl)-4-quinazolinamine.
15. A method of treating an-indication-mediated by Rho-kinase, comprising administering a compound of claim 1.
16. A method of treating an indication mediated by Rho-kinase, comprising administering a compound of claim 13.
17. A method of treating an indication mediated by Rho-kinase, comprising administering a compound of claim 14.
18. A method of treating hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, cancer of the breast, colon, prostate, ovaries, brain or lung, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction, comprising administering to a host in need thereof a compound according to claim 1.
19. A method of treating hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, cancer of the breast, colon, prostate, ovaries, brain or lung, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction, comprising administering to a host in need thereof a compound according to claim 13.
20. A method of treating hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, cancer of the breast, colon, prostate, ovaries, brain or lung, thrombotic disorders, asthma, glaucoma and osteoporosis or erectile dysfunction, comprising administering to a host in need thereof a compound according to claim 14.
21. A process according to claim 15, wherein the host is a human.
22. A process according to claim 16, wherein the host is a human.
23. A process according to claim 17, wherein the host is a human.
24. A process according to claim 18, wherein the host is a human.
25. A process according to claim 19, wherein the host is a human.
26. A process according to claim 20, wherein the host is a human.
27. A process for the preparation of a compound of claim l, comprising (a) reacting a compound of formula II
with a compound of formula III
in the presence of a base, to produce a compound of formula IV
and optionally further reacting IV with arylboronic acid or A-NH2, or (b) reacting a substituted benzoyl chloride with dimethylamine to produce a compound of formula V
wherein R''' is (i) C1-C10 alkyl or C2-C10-alkenyl, each optionally substituted with halogen up to perhalo; (ii) C3-C10 cycloalkyl; (iii) aryl; (iv) heteroaryl; (v) halogen;
(vi) -CO-ORB; (vii) -CO-RB; (viii) cyano; (ix) -ORB, (x) (x) -NR8R13; (xi) nitro; (xii) -CO-NR8R9;
(xiii) -C1-10-alkyl-NR8R9;(xiv) -NR8-CO-R12; (xv) -NR8-CO-OR9; (xvi) -NR8-SO2-R9; (xvii) -SR8; (xviii) -SO2-RB; (xix) -SO2-NR8R9; or (xx) NR8-CO-NHR9, reacting V with chloro-2-amino-benzonitrile to produce a compound of formula VI
and reacting VI with aminoindazole.
with a compound of formula III
in the presence of a base, to produce a compound of formula IV
and optionally further reacting IV with arylboronic acid or A-NH2, or (b) reacting a substituted benzoyl chloride with dimethylamine to produce a compound of formula V
wherein R''' is (i) C1-C10 alkyl or C2-C10-alkenyl, each optionally substituted with halogen up to perhalo; (ii) C3-C10 cycloalkyl; (iii) aryl; (iv) heteroaryl; (v) halogen;
(vi) -CO-ORB; (vii) -CO-RB; (viii) cyano; (ix) -ORB, (x) (x) -NR8R13; (xi) nitro; (xii) -CO-NR8R9;
(xiii) -C1-10-alkyl-NR8R9;(xiv) -NR8-CO-R12; (xv) -NR8-CO-OR9; (xvi) -NR8-SO2-R9; (xvii) -SR8; (xviii) -SO2-RB; (xix) -SO2-NR8R9; or (xx) NR8-CO-NHR9, reacting V with chloro-2-amino-benzonitrile to produce a compound of formula VI
and reacting VI with aminoindazole.
28. A process for preparing comprising reacting 3-fluoro-4-phenylbenzoic acid with 4-bromo-2-filuorobiphenyl to produce 2[(3-fluoro-4-phenylphenyl)carbonylamino]benzamide cyclizing to produce 2-(3-fluoro-l,1'-biphenyl-4-yl)-4(3H)-quinazolinone reacting to produce 4-chloro-2-(3-fluoro-4-phenylphenyl)quinazoline and then reacting with aminoindazole to produce
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27797401P | 2001-03-23 | 2001-03-23 | |
US60/277,974 | 2001-03-23 | ||
US31534101P | 2001-08-29 | 2001-08-29 | |
US60/315,341 | 2001-08-29 | ||
PCT/US2002/008659 WO2002076976A2 (en) | 2001-03-23 | 2002-03-22 | Rho-kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2441492A1 true CA2441492A1 (en) | 2002-10-03 |
CA2441492C CA2441492C (en) | 2011-08-09 |
Family
ID=26958819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2441492A Expired - Fee Related CA2441492C (en) | 2001-03-23 | 2002-03-22 | Rho-kinase inhibitors |
Country Status (20)
Country | Link |
---|---|
US (3) | US20030125344A1 (en) |
EP (1) | EP1370553B1 (en) |
JP (1) | JP4329003B2 (en) |
AR (1) | AR035791A1 (en) |
AT (1) | ATE325795T1 (en) |
AU (1) | AU2002250394A1 (en) |
CA (1) | CA2441492C (en) |
CY (1) | CY1107475T1 (en) |
DE (1) | DE60211317T2 (en) |
DK (1) | DK1370553T3 (en) |
ES (1) | ES2264477T3 (en) |
HK (1) | HK1061030A1 (en) |
HN (1) | HN2002000067A (en) |
MX (1) | MXPA03008658A (en) |
MY (1) | MY134783A (en) |
PE (1) | PE20021011A1 (en) |
PT (1) | PT1370553E (en) |
TW (1) | TWI261055B (en) |
UY (1) | UY27224A1 (en) |
WO (1) | WO2002076976A2 (en) |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2002000067A (en) * | 2001-03-23 | 2003-10-24 | Bayer Healthcare Llc | INHIBITORS OF THE RHO - QUINASA. |
WO2002076977A2 (en) * | 2001-03-23 | 2002-10-03 | Bayer Corporation | Rho-kinase inhibitors |
EP1403255A4 (en) * | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | Rho KINASE INHIBITORS |
JP4505228B2 (en) * | 2002-01-10 | 2010-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Rho-kinase inhibitor |
US7645878B2 (en) * | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
CN100425241C (en) | 2002-08-29 | 2008-10-15 | 参天制药株式会社 | Glaucoma-treating agent consisting of RHo kinase inhibitor and prostaglandin |
WO2004087056A2 (en) | 2003-03-28 | 2004-10-14 | Scios Inc. | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ |
GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
WO2004092196A2 (en) * | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
US20050014783A1 (en) * | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
US20080146562A1 (en) * | 2003-08-08 | 2008-06-19 | Ulysses Pharmaceutical Products Inc., | Halogenated quinazolinyl nitrofurans as antibacterial agents |
CA2534405A1 (en) * | 2003-08-08 | 2005-02-17 | Ulysses Pharmaceutical Products Inc. | Halogenated quinazolinyl nitrofurans as antibacterial agents |
US7547779B2 (en) * | 2003-10-06 | 2009-06-16 | Glaxo Group Limited | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors |
EP1689393A4 (en) * | 2003-10-06 | 2008-12-17 | Glaxo Group Ltd | Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors |
JP2007507549A (en) * | 2003-10-06 | 2007-03-29 | グラクソ グループ リミテッド | Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors |
EP1679308B1 (en) | 2003-10-15 | 2013-07-24 | Ube Industries, Ltd. | Novel indazole derivative |
DE10357510A1 (en) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroaryl-substituted benzenes |
AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
KR20070026390A (en) | 2004-01-23 | 2007-03-08 | 암젠 인코포레이션 | Compounds and methods of use |
ATE413389T1 (en) | 2004-02-03 | 2008-11-15 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES |
DE102004017438A1 (en) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituted phenylaminopyrimidines |
CN1988907B (en) * | 2004-06-01 | 2010-12-22 | 弗吉尼亚大学专利基金会 | Dual small molecule inhibitors of cancer and angiogenesis |
CA2569404A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
JP2007269629A (en) * | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | Quinazoline derivative |
TW200626157A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HCV inhibiting bi-cyclic pyrimidines |
CA2587642C (en) | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
US20080207677A1 (en) * | 2004-12-31 | 2008-08-28 | Gpc Biotech Ag | Napthyridine Compounds As Rock Inhibitors |
JP2006219395A (en) * | 2005-02-09 | 2006-08-24 | Koei Chem Co Ltd | Method for producing bipyridine compound |
US8252806B2 (en) | 2005-03-14 | 2012-08-28 | Neurosearch A/S | Potassium channel modulating agents and their medical use |
CR9465A (en) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | PHARMACOCINETICALLY IMPROVED COMPOUNDS |
ATE517897T1 (en) | 2005-03-25 | 2011-08-15 | Tibotec Pharm Ltd | HETEROBICYCLIC INHIBITORS OF HVC |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
AR056347A1 (en) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS |
PL1899322T3 (en) | 2005-06-28 | 2010-02-26 | Sanofi Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
US7618984B2 (en) | 2005-08-30 | 2009-11-17 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
CA2644910C (en) * | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
TW200815398A (en) | 2006-06-08 | 2008-04-01 | Ube Industries | A novel indazole derivative having spirocyclic structure in the side chain |
WO2007146230A2 (en) * | 2006-06-14 | 2007-12-21 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
MX2009006081A (en) * | 2006-12-08 | 2009-06-17 | Irmc Llc | Compounds and compositions as protein kinase inhibitors. |
EA019966B1 (en) | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Compounds and compositions as protein kinase inhibitors |
WO2008079945A2 (en) * | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
EP2118075A1 (en) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
US7964613B2 (en) | 2007-02-28 | 2011-06-21 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
KR101246392B1 (en) | 2007-07-02 | 2013-03-21 | 아사히 가세이 파마 가부시키가이샤 | Sulfonamide compound, and crystal thereof |
US9248125B2 (en) | 2007-08-29 | 2016-02-02 | Senju Pharmaceutical Co., Ltd. | Agent for promoting corneal endothelial cell adhesion |
UA101357C2 (en) | 2008-02-07 | 2013-03-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Normal;heading 1;heading 2;heading 3;SPIROCYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND METHOD FOR THEIR PRODUCTION |
JP5739802B2 (en) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | 4- (3-Chloro-2-fluoroanilino) -7-methoxy-6-{[1- (N-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline fumarate |
US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
CN101463014B (en) * | 2008-12-26 | 2013-07-10 | 复旦大学 | Diaryl benzo pyridine derivative, and its pharmaceutical composition and use thereof |
MX2011009568A (en) * | 2009-03-09 | 2011-12-06 | Surface Logix Inc | Rho kinase inhibitors. |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
DK2421957T3 (en) | 2009-04-22 | 2021-01-25 | Viacyte Inc | CELL COMPOSITIONS DERIVED FROM DEDIFFERENTIATED PROGRAMMED CELLS |
MX337982B (en) | 2009-10-16 | 2016-03-30 | Scripps Research Inst | Induction of pluripotent cells. |
AU2010315712B2 (en) | 2009-10-19 | 2014-04-17 | FUJIFILM Cellular Dynamics, Inc. | Cardiomyocyte production |
CA2780333C (en) | 2009-11-17 | 2016-05-24 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
AR079814A1 (en) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | HETEROCICLICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES |
US8759363B2 (en) | 2010-01-28 | 2014-06-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Quinazoline-based T cell proliferation inhibitors |
US20130053375A1 (en) * | 2010-05-07 | 2013-02-28 | Glaxo Group Limited | Amino-quinolines as kinase inhibitors |
ES2670842T3 (en) | 2010-06-15 | 2018-06-01 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
CN103168033A (en) | 2010-10-05 | 2013-06-19 | 普渡制药公司 | Quinazoline compounds as sodium channel blockers |
EP2655601A4 (en) | 2010-12-22 | 2014-09-10 | Fate Therapeutics Inc | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
WO2012122011A2 (en) | 2011-03-04 | 2012-09-13 | Glaxosmithkline Llc | Amino-quinolines as kinase inhibitors |
DK2694644T3 (en) | 2011-03-30 | 2018-04-16 | Cellular Dynamics Int Inc | Priming of pluripotent stem cells for neural differentiation |
JP6121658B2 (en) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | Therapeutic compounds and related methods of use |
US20130040302A1 (en) | 2011-07-11 | 2013-02-14 | Thomas J. Burke | Methods for cell reprogramming and genome engineering |
TWI547494B (en) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | Amino quinazolines as kinase inhibitors |
PT2788472T (en) | 2011-12-06 | 2019-04-01 | Astellas Inst For Regenerative Medicine | Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof |
EP3553169B1 (en) | 2011-12-28 | 2021-11-03 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
EP2628482A1 (en) | 2012-02-17 | 2013-08-21 | Academisch Medisch Centrum | Rho kinase inhiitors for use in the treatment of neuroblastoma |
EP2826855B1 (en) | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
WO2013151186A1 (en) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | Method for inducing erythropoietin-producing cell |
TWI592417B (en) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | Prodrugs of amino quinazoline kinase inhibitor |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
JP2016507496A (en) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
JP2016510000A (en) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
WO2014128622A1 (en) | 2013-02-21 | 2014-08-28 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
JP6602288B2 (en) | 2013-04-03 | 2019-11-06 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | Methods and compositions for culturing endoderm progenitor cells in suspension |
WO2014168264A1 (en) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | Method for inducing alveolar epithelium progenitor cells |
CA2915085C (en) | 2013-06-11 | 2021-04-27 | Kyoto University | Method for producing renal progenitor cells and drug comprising the same |
EP3010503B1 (en) | 2013-06-21 | 2020-03-11 | Zenith Epigenetics Ltd. | Novel bicyclic bromodomain inhibitors |
CA2915622C (en) | 2013-06-21 | 2020-08-18 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
WO2015016371A1 (en) | 2013-07-30 | 2015-02-05 | 京都府公立大学法人 | Corneal endothelial cell marker |
CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
JP6378183B2 (en) | 2013-08-07 | 2018-08-22 | 国立大学法人京都大学 | Method for producing pancreatic hormone-producing cells |
MY184219A (en) | 2013-09-05 | 2021-03-26 | Univ Kyoto | New method for inducing dopamine-producing neural precursor cells |
WO2015054317A1 (en) * | 2013-10-07 | 2015-04-16 | Kadmon Corporation, Llc | Rho kinase inhibitors |
RU2712967C2 (en) | 2013-10-31 | 2020-02-03 | Киото Прифекчурал Паблик Юниверсити Корпорэйшн | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
MX2016006915A (en) | 2013-11-27 | 2017-01-23 | Kyoto Prefectural Public Univ Corp | Application of laminin to corneal endothelial cell culture. |
WO2015112739A1 (en) * | 2014-01-22 | 2015-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and method for treating parp1-deficient cancers |
KR102340553B1 (en) | 2014-03-04 | 2021-12-21 | 페이트 세러퓨틱스, 인코포레이티드 | Improved reprogramming methods and cell culture platforms |
ES2939807T3 (en) | 2014-03-21 | 2023-04-27 | Fujifilm Cellular Dynamics Inc | Production of midbrain dopaminergic neurons and methods for their utilization |
CN106536718B (en) | 2014-05-21 | 2021-04-27 | 国立大学法人京都大学 | Method for producing pancreatic islet cells and therapeutic agent for pancreatic disease containing pancreatic islet cells |
SG10201806498RA (en) | 2014-06-27 | 2018-08-30 | Univ California | Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof |
CN105367555B (en) * | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | Substituted heteroaryl compound and combinations thereof and purposes |
WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
EP3230277B1 (en) | 2014-12-11 | 2019-09-18 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
EP3283479B1 (en) * | 2015-04-01 | 2022-12-14 | Rigel Pharmaceuticals, Inc. | Tgf-beta inhibitors |
EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
WO2017064119A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
EP3362570A4 (en) | 2015-10-16 | 2019-03-20 | Fate Therapeutics, Inc. | Platform for the induction & maintenance of ground state pluripotency |
CA3003145A1 (en) | 2015-10-30 | 2017-05-04 | Gay M. Crooks | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
EP3416658B1 (en) | 2016-02-15 | 2023-03-22 | Kyoto Prefectural Public University Corporation | Human functional corneal endothelial cell and application thereof |
AU2017254268B2 (en) | 2016-04-22 | 2023-03-16 | Kyoto University | Method for producing dopamine-producing neural precursor cells |
EP3500664B1 (en) | 2016-08-16 | 2021-09-22 | FUJIFILM Cellular Dynamics, Inc. | Methods for differentiating pluripotent cells |
WO2018048747A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324251A1 (en) | 2016-09-08 | 2019-03-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN106518790B (en) * | 2016-11-02 | 2019-01-15 | 河南省商业科学研究所有限责任公司 | A kind of synthetic method of 2,4- dichloroquinazoline |
KR20190093214A (en) | 2016-12-13 | 2019-08-08 | 베타 테라퓨틱스 피티와이 리미티드 | Heparanase inhibitors and uses thereof |
US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
WO2018216743A1 (en) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell |
AU2018294054B2 (en) | 2017-06-30 | 2022-05-26 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
EP3421465B1 (en) | 2017-06-30 | 2022-10-26 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
US20210363483A1 (en) | 2017-11-10 | 2021-11-25 | Regenesis Science Co., Ltd. | Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease |
CA3082643A1 (en) | 2017-11-14 | 2019-05-23 | The Schepens Eye Research Institute, Inc. | Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
US11446273B2 (en) | 2017-12-21 | 2022-09-20 | Santen Pharmaceutical Co., Ltd. | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor |
WO2019131940A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Pluripotent stem cell aggregation inhibitor |
WO2019131941A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Cell aggregation inhibitor |
WO2019131942A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Cell aggregation promoting agent |
CN111788303A (en) | 2018-02-19 | 2020-10-16 | 大日本住友制药株式会社 | Cell aggregate, mixture of cell aggregates, and method for producing same |
JP7357369B2 (en) | 2018-07-23 | 2023-10-06 | 国立大学法人京都大学 | Novel renal progenitor cell marker and method for enriching renal progenitor cells using it |
US20210292766A1 (en) | 2018-08-29 | 2021-09-23 | University Of Massachusetts | Inhibition of Protein Kinases to Treat Friedreich Ataxia |
WO2020045642A1 (en) | 2018-08-31 | 2020-03-05 | 学校法人同志社 | Composition and method for preserving or culturing ocular cells |
EP3862424A4 (en) | 2018-10-02 | 2022-06-29 | The Doshisha | Method and vessel for preserving corneal endothelial cells |
UY38427A (en) | 2018-10-26 | 2020-05-29 | Novartis Ag | METHODS AND COMPOSITIONS FOR EYE CELL THERAPY |
WO2020130147A1 (en) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage |
WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
US20220169977A1 (en) | 2019-03-29 | 2022-06-02 | Kaneka Corporation | Cell population including pluripotent stem cells and production method thereof |
JPWO2020230832A1 (en) | 2019-05-15 | 2020-11-19 | ||
CA3173725A1 (en) | 2020-02-27 | 2021-09-02 | Kyoto Prefectural Public University Corporation | Functional human corneal endothelial cells and application thereof |
JP2023522784A (en) | 2020-04-27 | 2023-05-31 | ノバルティス アーゲー | Methods and compositions for ocular cell therapy |
WO2022149616A1 (en) | 2021-01-08 | 2022-07-14 | 国立大学法人京都大学 | Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids |
JP2024503021A (en) | 2021-01-11 | 2024-01-24 | インサイト・コーポレイション | Combination therapy including JAK pathway inhibitor and ROCK inhibitor |
KR20230165846A (en) | 2021-04-07 | 2023-12-05 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | Dopaminergic progenitor cells and methods of use |
CN117242173A (en) | 2021-05-03 | 2023-12-15 | 安斯泰来再生医药协会 | Method for producing mature corneal endothelial cells |
EP4353243A1 (en) | 2021-06-10 | 2024-04-17 | Ajinomoto Co., Inc. | Method for producing mesenchymal stem cells |
WO2023017848A1 (en) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells |
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US14679A (en) * | 1856-04-15 | Joel h | ||
US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
US5245038A (en) * | 1987-11-06 | 1993-09-14 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
EP0498722B1 (en) * | 1991-02-07 | 1997-07-30 | Roussel Uclaf | Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them |
MX9200299A (en) * | 1991-02-07 | 1992-12-01 | Roussel Uclaf | NEW NITROGENATED BICYCLE DERIVATIVES, THEIR PROCEDURE FOR PREPARING THE NEW INTERMEDIATE COMPOUNDS OBTAINED THEIR APPLICATION AS MEDICINES AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
US6645969B1 (en) * | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
EP1195372A1 (en) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
DE19608653A1 (en) * | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation |
PT912559E (en) * | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | HETEROCYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS TYROSINE KINASE |
PL331561A1 (en) * | 1996-08-12 | 1999-07-19 | Yoshitomi Pharmaceutical | Pharmaceutic composition containing an inhibitor of rho kinase |
AR012634A1 (en) * | 1997-05-02 | 2000-11-08 | Sugen Inc | QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE |
US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
WO2000010981A1 (en) * | 1998-08-21 | 2000-03-02 | Parker Hughes Institute | Quinazoline derivatives |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
WO2000039191A1 (en) * | 1998-12-23 | 2000-07-06 | Bayer Aktiengesellschaft | Polycarbonates with a low yellowness index |
GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
JP3270834B2 (en) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | Heteroaromatic bicyclic derivatives useful as anticancer agents |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
CZ306810B6 (en) * | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | The use of a quinazoline derivative as an inhibitor of angiogenesis |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
UA73993C2 (en) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
AU2001297619B2 (en) * | 2000-12-21 | 2006-06-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
HN2002000067A (en) * | 2001-03-23 | 2003-10-24 | Bayer Healthcare Llc | INHIBITORS OF THE RHO - QUINASA. |
IL161619A0 (en) * | 2001-11-03 | 2004-09-27 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
GB0128108D0 (en) * | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
JP4505228B2 (en) * | 2002-01-10 | 2010-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Rho-kinase inhibitor |
ATE381557T1 (en) * | 2002-01-23 | 2008-01-15 | Bayer Pharmaceuticals Corp | RHO KINASE INHIBITORS |
JP4608215B2 (en) * | 2002-02-01 | 2011-01-12 | アストラゼネカ アクチボラグ | Quinazoline compounds |
EP1603908B1 (en) * | 2003-03-12 | 2008-06-11 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
GB0318422D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
EP1928861B1 (en) * | 2005-09-20 | 2010-11-17 | AstraZeneca AB | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
-
2002
- 2002-03-22 HN HN2002000067A patent/HN2002000067A/en unknown
- 2002-03-22 TW TW091105591A patent/TWI261055B/en not_active IP Right Cessation
- 2002-03-22 US US10/103,566 patent/US20030125344A1/en not_active Abandoned
- 2002-03-22 DE DE60211317T patent/DE60211317T2/en not_active Expired - Lifetime
- 2002-03-22 MY MYPI20021020A patent/MY134783A/en unknown
- 2002-03-22 EP EP02719303A patent/EP1370553B1/en not_active Expired - Lifetime
- 2002-03-22 PE PE2002000224A patent/PE20021011A1/en not_active Application Discontinuation
- 2002-03-22 JP JP2002576234A patent/JP4329003B2/en not_active Expired - Fee Related
- 2002-03-22 AT AT02719303T patent/ATE325795T1/en active
- 2002-03-22 AR ARP020101069A patent/AR035791A1/en unknown
- 2002-03-22 DK DK02719303T patent/DK1370553T3/en active
- 2002-03-22 ES ES02719303T patent/ES2264477T3/en not_active Expired - Lifetime
- 2002-03-22 PT PT02719303T patent/PT1370553E/en unknown
- 2002-03-22 UY UY27224A patent/UY27224A1/en unknown
- 2002-03-22 WO PCT/US2002/008659 patent/WO2002076976A2/en active IP Right Grant
- 2002-03-22 CA CA2441492A patent/CA2441492C/en not_active Expired - Fee Related
- 2002-03-22 AU AU2002250394A patent/AU2002250394A1/en not_active Abandoned
- 2002-03-22 MX MXPA03008658A patent/MXPA03008658A/en active IP Right Grant
-
2004
- 2004-06-09 HK HK04104115A patent/HK1061030A1/en not_active IP Right Cessation
-
2006
- 2006-02-16 US US11/354,977 patent/US20060142313A1/en not_active Abandoned
- 2006-08-09 CY CY20061101118T patent/CY1107475T1/en unknown
-
2010
- 2010-02-02 US US12/698,386 patent/US20100137324A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2264477T3 (en) | 2007-01-01 |
PE20021011A1 (en) | 2003-02-01 |
JP4329003B2 (en) | 2009-09-09 |
EP1370553A2 (en) | 2003-12-17 |
DE60211317T2 (en) | 2007-04-12 |
HK1061030A1 (en) | 2004-09-03 |
WO2002076976A3 (en) | 2002-12-12 |
MY134783A (en) | 2007-12-31 |
DK1370553T3 (en) | 2006-09-11 |
UY27224A1 (en) | 2002-10-31 |
AR035791A1 (en) | 2004-07-14 |
CA2441492C (en) | 2011-08-09 |
EP1370553B1 (en) | 2006-05-10 |
MXPA03008658A (en) | 2005-04-11 |
ATE325795T1 (en) | 2006-06-15 |
HN2002000067A (en) | 2003-10-24 |
US20100137324A1 (en) | 2010-06-03 |
AU2002250394A1 (en) | 2002-10-08 |
DE60211317D1 (en) | 2006-06-14 |
JP2004524350A (en) | 2004-08-12 |
PT1370553E (en) | 2006-09-29 |
US20060142313A1 (en) | 2006-06-29 |
TWI261055B (en) | 2006-09-01 |
WO2002076976A2 (en) | 2002-10-03 |
US20030125344A1 (en) | 2003-07-03 |
CY1107475T1 (en) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2441492A1 (en) | Rho-kinase inhibitors | |
US7235559B1 (en) | Therapeutic quinazoline derivatives | |
US7547702B2 (en) | 4-amino-quinazolines | |
US8710044B2 (en) | Bicyclic azaheterocyclic carboxamides | |
EP1844022A1 (en) | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | |
JP2008502610A5 (en) | ||
CA2526430A1 (en) | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | |
AU2008251584B2 (en) | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-HT7 receptor antagonists | |
NZ549842A (en) | Novel compounds as opioid receptor modulators | |
AU2005227997A1 (en) | Pyrimidine derivatives and methods of treatment related to the use thereof | |
CN101619043A (en) | Quinazoline derivant and medical application thereof | |
RU2004129768A (en) | Bicyclic Pyridines and Pyrimidines as P38 Kinase Inhibitors | |
RU2008141510A (en) | NEW COMPOUNDS | |
CA2726040A1 (en) | Quinazoline derivatives | |
AU2017239625B2 (en) | Novel heterocyclic carboxamides as modulators of kinase activity | |
CA2479363A1 (en) | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | |
RU2006102869A (en) | Arylamino-substituted quinazolinone compounds | |
JP2007502298A5 (en) | ||
RU2006133264A (en) | 7H-pyrrolopyrimidine derivatives | |
Hamed et al. | Synthesis and Anti-Tumor Evaluation of Some New Tranilast Analogous |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140324 |